Public Puts Pressure On Hengrui Medicine To Address Quality Issues
This article was originally published in PharmAsia News
Executive Summary
After facing a lawsuit by Sanofi-Aventis over patent infringement, Hengrui Medicine now faces another challenge with reports of quality issues from Zhejiang Province State FDA
|
After facing a lawsuit by Sanofi-Aventis over patent infringement, Hengrui Medicine now faces another challenge with reports of quality issues from Zhejiang Province State FDA. Despite public concern over the safety of medicines, Hengrui has yet to address the issues with a public notice. The reported quality issues involve 58 failed batches of antibiotics, chemical drugs, and patented Chinese medicines, including a batch of papaverine hydrochloride injection that failed due to "visible foreign bodies." Hengrui Medicine attracted attention in October 2009 when investigations uncovered clarithromycin sustained-release tablets with abnormal levels of water content. (Click Here For More - Chinese Language) "Hengrui Medicine Entangled In 'Quality Gate'"- stock.hexun.com (8.04.10) |